FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110368003> ?p ?o ?g. }

• W2110368003 endingPage "996" @default.
• W2110368003 startingPage "990" @default.
• W2110368003 abstract "Objective. To assess the kinetics of response to certolizumab pegol (CZP), and association between rapid response and longterm outcomes, in patients with active rheumatoid arthritis (RA). Methods. This was a post-hoc analysis of the randomized, double-blind RAPID 1 study in patients who received methotrexate (MTX) and either CZP 200 mg subcutaneously or placebo every 2 weeks for 52 weeks. Clinical and radiographic outcomes at Week 52 were evaluated based on the Disease Activity Score 28 (DAS28) ≥ 1.2 and American College of Rheumatology 20% (ACR20) responses at Week 6 and Week 12. Results. Clinical responses [European League Against Rheumatism (EULAR), DAS28 ≥ 1.2, and ACR20 responses] were rapid in CZP-treated patients. Week 12 DAS28 ≥ 1.2 responders had better clinical and radiographic outcomes at Week 52 compared with nonresponders. Among Week 12 responders, incremental benefit of earlier response was observed: Week 6 DAS28 ≥ 1.2 responders and ACR20 responders had significantly higher ACR response rates and were more likely to achieve remission at Week 52 than Week 12 responders. Patients with a clinical response at Week 6 had faster, more meaningful sustained improvements in patient-derived outcomes than those responding by Week 12 only. Conclusion. Rapid attainment of clinical response in patients with RA is associated with improved longterm outcomes. Analysis of the kinetics of response to CZP during the first 12 weeks of therapy potentially permits informed prediction of clinical success or need to alter treatment. In patients not achieving a clinical response at Week 12 treatment adjustment should be considered. Trial registration NCT00152386 ." @default.
• W2110368003 created "2016-06-24" @default.
• W2110368003 creator A5000754711 @default.
• W2110368003 creator A5008811878 @default.
• W2110368003 creator A5014366521 @default.
• W2110368003 creator A5046261111 @default.
• W2110368003 creator A5047233668 @default.
• W2110368003 creator A5052078671 @default.
• W2110368003 creator A5073269240 @default.
• W2110368003 creator A5078402239 @default.
• W2110368003 creator A5080646462 @default.
• W2110368003 creator A5081778211 @default.
• W2110368003 creator A5090753435 @default.
• W2110368003 date "2011-03-01" @default.
• W2110368003 modified "2023-09-27" @default.
• W2110368003 title "Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial" @default.
• W2110368003 cites W1942793553 @default.
• W2110368003 cites W1979364075 @default.
• W2110368003 cites W1985004174 @default.
• W2110368003 cites W1987506287 @default.
• W2110368003 cites W1994423552 @default.
• W2110368003 cites W2000905503 @default.
• W2110368003 cites W2006566716 @default.
• W2110368003 cites W2035733184 @default.
• W2110368003 cites W2046628605 @default.
• W2110368003 cites W2051986755 @default.
• W2110368003 cites W2061120890 @default.
• W2110368003 cites W2091732273 @default.
• W2110368003 cites W2098767548 @default.
• W2110368003 cites W2099199787 @default.
• W2110368003 cites W2109217002 @default.
• W2110368003 cites W2109237866 @default.
• W2110368003 cites W2110177517 @default.
• W2110368003 cites W2130498680 @default.
• W2110368003 cites W2134171514 @default.
• W2110368003 cites W2152348310 @default.
• W2110368003 cites W2156996668 @default.
• W2110368003 cites W2159106700 @default.
• W2110368003 cites W2163817180 @default.
• W2110368003 cites W2166732840 @default.
• W2110368003 cites W2169713004 @default.
• W2110368003 cites W3006080604 @default.
• W2110368003 doi "https://doi.org/10.3899/jrheum.100935" @default.
• W2110368003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21362764" @default.
• W2110368003 hasPublicationYear "2011" @default.
• W2110368003 type Work @default.
• W2110368003 sameAs 2110368003 @default.
• W2110368003 citedByCount "41" @default.
• W2110368003 countsByYear W21103680032012 @default.
• W2110368003 countsByYear W21103680032013 @default.
• W2110368003 countsByYear W21103680032014 @default.
• W2110368003 countsByYear W21103680032015 @default.
• W2110368003 countsByYear W21103680032016 @default.
• W2110368003 countsByYear W21103680032017 @default.
• W2110368003 countsByYear W21103680032018 @default.
• W2110368003 countsByYear W21103680032020 @default.
• W2110368003 countsByYear W21103680032021 @default.
• W2110368003 crossrefType "journal-article" @default.
• W2110368003 hasAuthorship W2110368003A5000754711 @default.
• W2110368003 hasAuthorship W2110368003A5008811878 @default.
• W2110368003 hasAuthorship W2110368003A5014366521 @default.
• W2110368003 hasAuthorship W2110368003A5046261111 @default.
• W2110368003 hasAuthorship W2110368003A5047233668 @default.
• W2110368003 hasAuthorship W2110368003A5052078671 @default.
• W2110368003 hasAuthorship W2110368003A5073269240 @default.
• W2110368003 hasAuthorship W2110368003A5078402239 @default.
• W2110368003 hasAuthorship W2110368003A5080646462 @default.
• W2110368003 hasAuthorship W2110368003A5081778211 @default.
• W2110368003 hasAuthorship W2110368003A5090753435 @default.
• W2110368003 hasBestOaLocation W21103680031 @default.
• W2110368003 hasConcept C126322002 @default.
• W2110368003 hasConcept C142724271 @default.
• W2110368003 hasConcept C168563851 @default.
• W2110368003 hasConcept C1862650 @default.
• W2110368003 hasConcept C198451711 @default.
• W2110368003 hasConcept C204787440 @default.
• W2110368003 hasConcept C27081682 @default.
• W2110368003 hasConcept C2776215756 @default.
• W2110368003 hasConcept C2777226972 @default.
• W2110368003 hasConcept C2777489490 @default.
• W2110368003 hasConcept C2777575956 @default.
• W2110368003 hasConcept C535046627 @default.
• W2110368003 hasConcept C67761136 @default.
• W2110368003 hasConcept C71924100 @default.
• W2110368003 hasConceptScore W2110368003C126322002 @default.
• W2110368003 hasConceptScore W2110368003C142724271 @default.
• W2110368003 hasConceptScore W2110368003C168563851 @default.
• W2110368003 hasConceptScore W2110368003C1862650 @default.
• W2110368003 hasConceptScore W2110368003C198451711 @default.
• W2110368003 hasConceptScore W2110368003C204787440 @default.
• W2110368003 hasConceptScore W2110368003C27081682 @default.
• W2110368003 hasConceptScore W2110368003C2776215756 @default.
• W2110368003 hasConceptScore W2110368003C2777226972 @default.
• W2110368003 hasConceptScore W2110368003C2777489490 @default.
• W2110368003 hasConceptScore W2110368003C2777575956 @default.
• W2110368003 hasConceptScore W2110368003C535046627 @default.
• W2110368003 hasConceptScore W2110368003C67761136 @default.
• W2110368003 hasConceptScore W2110368003C71924100 @default.

• next